Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 1.00 |
| ▸ | UGCG | Q16739 | 2/20 | 0.61 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.61 |
| ▸ | SMPD2 | O60906 | 2/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611869 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL4234738 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL13930310 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL8341673 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL4239949 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL13930311 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL8340882 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL13930314 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL27657658 | 0.94 | ASAH1 (0.89) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL12435699 | 0.92 | ASAH1 (0.85) | ASAH1ALDH1A1ACER2UGCGCERT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196859-A1 | Oligodendrocyte Precursor Cell Composition and Methods of Use | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-08-06 | — | — | US | claimed |
| US-20090054526-A1 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | UNIVERSITY OF COPENHAGEN (DK) | 2009-02-26 | — | — | US | claimed |
| CN-101247797-A | Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders | RHEOSCIENCE AS (DK) | 2008-08-20 | — | — | CN | claimed |
| EP-1250119-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2007-10-03 | — | — | EP | claimed |
| EP-1250119-A2 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2002-10-23 | — | — | EP | claimed |
| WO-2001054654-A2 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| US-6235737-B1 | APPLYING COMPOUND TO ADJUST CERAMIDE CONCENTRATION | GILLETTE COMPANY, THE | 2001-05-22 | — | — | US | claimed |
| WO-2022261752-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PARKER ALEX (CA) | 2022-12-22 | — | — | WO | disclosed |
| US-10780076-B2 | Inhibition of cancer cell motility | NORTHWESTERN UNIVERSITY (US) | 2020-09-22 | — | — | US | disclosed |
| CN-109288827-B | Application of ceramidase inhibitor D-e-MAPP in preparation of medicine for improving acute pancreatitis | 桂林医学院附属医院 | 2020-05-26 | — | — | CN | disclosed |
| US-20190201373-A1 | INHIBITION OF CANCER CELL MOTILITY | NORTHWESTERN UNIVERSITY | 2019-07-04 | — | — | US | disclosed |
| US-10231949-B2 | Inhibition of cancer cell motility | NORTHWESTERN UNIVERSITY (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180153853-A1 | INHIBITION OF CANCER CELL MOTILITY | NORTHWESTERN UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| US-20050153934-A1 | Chaperone-based therapy for Niemann-Pick disease | NIH-DEITR | 2005-07-14 | — | — | US | disclosed |
| WO-2005051331-A2 | CHAPERONE-BASED THERAPY FOR NIEMANN-PICK DISEASE | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004029203-A2 | COMPOSITIONS AND METHODS FOR ENRICHMENT OF NEURAL STEM CELLS USING CERAMIDE ANALOGS | BRESAGEN, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
| EP-1250119-A2 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| US-6410597-B1 | ANTIINFLAMMATORY AGENTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-06-25 | — | — | US | disclosed |
| WO-2001054654-A2 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| US-6235737-B1 | APPLYING COMPOUND TO ADJUST CERAMIDE CONCENTRATION | GILLETTE COMPANY, THE | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054526-A1 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | LIPE, PNLIP, FAAH2 | ASAH1 21/4885ALDH1A1 1720/4885ACER2 14/4885 |
| US-10780076-B2 | Inhibition of cancer cell motility | MMP26, MKI67, EPCAM | ASAH1 1336/4885ALDH1A1 1222/4885ACER2 2861/4885 |
| US-20180153853-A1 | INHIBITION OF CANCER CELL MOTILITY | MMP26, MKI67, EPCAM | ASAH1 1336/4885ALDH1A1 1222/4885ACER2 2861/4885 |
| US-20050153934-A1 | Chaperone-based therapy for Niemann-Pick disease | GBA1, MAN2B1, SMPD1 | ASAH1 6/4885ALDH1A1 3994/4885ACER2 28/4885 |
| US-10231949-B2 | Inhibition of cancer cell motility | MMP26, MKI67, EPCAM | ASAH1 1336/4885ALDH1A1 1222/4885ACER2 2861/4885 |
| US-20190201373-A1 | INHIBITION OF CANCER CELL MOTILITY | MMP26, MKI67, EPCAM | ASAH1 1336/4885ALDH1A1 1222/4885ACER2 2861/4885 |
| US-20090196859-A1 | Oligodendrocyte Precursor Cell Composition and Methods of Use | SGMS1, S1PR1, S1PR3 | ASAH1 81/4885ALDH1A1 1107/4885ACER2 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.